

Symposium 218



# Current Challenges of Inflammatory Bowel Disease

March 6–7, 2020  
Hyatt Regency Hotel  
Mexico City, Mexico



## Program

Awarded  
with  
**12**  
CME credits

▶	Preface . . . . .	2
▶	Scientific Program . . . . .	4
▶	Poster Abstracts . . . . .	8
▶	List of Speakers, Moderators and Scientific Organizers . . . . .	13
▶	Information . . . . .	16

12 credit hours (CME) have been awarded for Symposium 218 by the European Union of Medical Specialists (UEMS).

## Preface

Dear colleagues and friends,

I am delighted to welcome you to the first Symposium, organized by Falk Foundation e.V., in Mexico City on March 6 and 7, 2020. This will be the second Symposium held in Latin America after more than two decades. It is a great privilege to have this event in Mexico where the incidence and prevalence of Inflammatory Bowel Disease (IBD) has increased importantly in the last decade. Mexico City, capital of the country, lies at an altitude of more than 2,200 meters in the Anáhuac Valley, surrounded by mighty mountain ranges and two magnificent snow-covered volcanoes, Popocatepetl and Iztaccíhuatl. This city is one of the world's largest cities, both in terms of population and area, most of the city's best tourist attractions and popular things to do are in the historic city center, a 15-square-kilometer UNESCO World Heritage Site containing more than 1,400 important buildings from the 16th to 19th centuries, as well as several museums such as Frida Kahlo Museum, the National Museum of Anthropology, the Palace of Fine Arts and others.

The theme of this Symposium in Mexico City is "Current Challenges of Inflammatory Bowel Disease". The linear program has seven selected sessions, structured around epidemiology, monitoring tools, conventional and biological treatment, new emerging therapeutic approaches, surgical issues and special situations focused on clinical practice with direct relevance to patient care, as well as poster presentations.

Our aims remain to provide an exciting academic program with latest and best scientific information and education in order to share and discuss the most relevant topics of IBD approach for improving outcomes and quality of life in patients with IBD.

Thanks to the generosity of Falk Foundation and all our international IBD experts for all time, effort and dedication in this important event.

On behalf of the organizing committee, Maria Abreu, Fernando Gomollon and Francisco Bosques, I extend a warm welcome to you all in Mexico City!

Yours sincerely,

Jesús Yamamoto-Furusho  
Chair of the Organizing Committee



# Current Challenges of Inflammatory Bowel Disease

March 6–7, 2020

Hyatt Regency Hotel  
Mexico City, Mexico

**Start of Registration:**

Thursday, March 5, 2020  
16.00 - 21.00 h  
at the congress office

**Setting Up of Poster Session:**

Thursday, March 5, 2020  
16.00 - 21.00 h

**Congress Venue:**

Hyatt Regency Hotel  
Campos Elíseos 204  
Polanco Chapultepec  
11560 Mexico City  
Mexico

**Symposium 218 is organized  
by Falk Foundation e.V.**

**Scientific Organization:**

Prof. Dr. Jesús K. Yamamoto-Furusho  
Clinica de Enfermedad Inflammatoria  
Intestinal  
Departamento de Gastroenterología  
Instituto Nacional de Ciencias  
Médicas y Nutrición Salvador Zubirán  
Segundo piso, Calle Vasco de Quiroga 15  
Colonia Belisario Domínguez Sección XVI  
Delegación Tlalpan. C.P.  
14080 Ciudad de México  
Mexico  
Telephone: +52-5555-733-418  
Telefax: +52-5556-060-944  
E-mail: kazuofurusho@hotmail.com

**Scientific Co-Organization:**

M.T. Abreu, Miami (USA)  
F.J. Bosques Padilla, Monterrey (Mexico)  
F. Gomollón, Zaragoza (Spain)

**Official Language:**

English  
Translation into Spanish



# Friday, March 6, 2020

**9.00** Welcome and Introduction

J.K. Yamamoto-Furusho,  
Mexico City

## Session I

### Emerging epidemiology of IBD worldwide

**Chair:** M.T. Abreu, Miami; F.J. Bosques Padilla, Monterrey

- |              |  |                                       |
|--------------|--|---------------------------------------|
| <b>9.10</b>  | The old world of Europe: Has the incidence and prevalence of IBD stabilized? | P. Munkholm,<br>Copenhagen            |
| <b>9.35</b>  | How studying immigrants can edify the epidemiology of IBD                    | G. Kaplan,<br>Calgary                 |
| <b>10.00</b> | Epidemiology of IBD in Asia  | Z. Ran,<br>Shanghai                   |
| <b>10.25</b> | Rising incidence of inflammatory bowel disease in Mexico and Latin America?  | J.K. Yamamoto-Furusho,<br>Mexico City |
| <b>10.50</b> | <b>Coffee break with poster session</b>                                      |                                       |

## Session II

### Monitoring tools in IBD

**Chair:** M. Duijvestein, Amsterdam; R. Panaccione, Calgary

- |              |  |                            |
|--------------|--|----------------------------|
| <b>11.20</b> | Serological and fecal biomarkers   | M.C. Dubinsky,<br>New York |
| <b>11.45</b> | Chromoendoscopy vs. digital technology for the detection of lesions and dysplasia in UC patients | A.S. Cheifetz,<br>Boston   |
| <b>12.10</b> | What radiological tool is better in Crohn's disease patients?                                    | J. Rimola,<br>Barcelona    |
| <b>12.35</b> | Does histological remission matter - View of a pathologist also on neoplasia                     | M. Vieth,<br>Bayreuth      |
| <b>13.00</b> | <b>Lunch break with poster session</b>   |                            |

# ▶ Friday, March 6, 2020

## Session III Conventional treatment still useful in IBD?

**Chair:** B.E. Sands, New York; S. Schreiber, Kiel

- |              |   |                            |
|--------------|---|----------------------------|
| <b>14.30</b> | Patient profile for the use of 5-ASA in IBD               | A.H. Steinhart,<br>Toronto |
| <b>14.55</b> | Topical vs. systemic steroids in IBD                      | A. Dignass,<br>Frankfurt   |
| <b>15.20</b> | Role of thiopurines and methotrexate in IBD               | F. Carbonnel,<br>Paris     |
| <b>15.45</b> | Challenges in the management of severe ulcerative colitis | J.O. Lindsay,<br>London    |
| <b>16.10</b> | <b>Coffee break with poster session</b>                   |                            |

## Session IV Practical issues in the treatment of IBD with anti-TNF therapy

**Chair:** S. Ghosh, Birmingham; W.J. Sandborn, San Diego

- |              |  |                              |
|--------------|--|------------------------------|
| <b>16.40</b> | Top-down vs. step-up approach                          | E.V. Loftus,<br>Rochester    |
| <b>17.05</b> | Empirical optimization vs. therapeutic drug monitoring | M.T. Abreu,<br>Miami         |
| <b>17.30</b> | Is anti-TNF therapy for ever?                          | M. Duijvestein,<br>Amsterdam |
| <b>17.55</b> | Safety concerns of TNF $\alpha$ antagonists            | S. Singh,<br>San Diego       |
| <b>18.20</b> | <b>Networking with light refreshments</b>              |                              |



# Saturday, March 7, 2020

## Session V

### Surgical issues in IBD

**Chair:** W.A. Bemelman, Amsterdam; A. D'Hoore, Leuven

- |              |   |                             |
|--------------|---|-----------------------------|
| <b>9.00</b>  | Small bowel resection vs. stricturoplasty           | W.A. Bemelman,<br>Amsterdam |
| <b>9.25</b>  | Minimal invasive surgery: A better approach?        | F. Remzi,<br>New York       |
| <b>9.50</b>  | Role of mesenteric fat in the clinical course of CD | A. D'Hoore,<br>Leuven       |
| <b>10.15</b> | Management of refractory pouchitis                  | B. Shen,<br>New York        |
| <b>10.40</b> | <b>Coffee break with poster session</b>             |                             |

## Session VI

### Challenges in IBD

**Chair:** F. Gomollón, Zaragoza; G. Rogler, Zurich

- |              |  |                                  |
|--------------|--|----------------------------------|
| <b>11.10</b> | Management of psycho-social issues for IBD patients and their families | C.N. Bernstein,<br>Winnipeg      |
| <b>11.35</b> | The pediatric-adult transition: How to bridge the change               | J. Martín de Carpi,<br>Barcelona |
| <b>12.00</b> | <b>Presentation of Poster Awards</b>                                   |                                  |
| <b>12.15</b> | Telemedicine: The new medicine for IBD?                                | M.T. Abreu,<br>Miami             |
| <b>12.40</b> | Personalized medicine for the treatment of IBD                         | F. Gomollón,<br>Zaragoza         |
| <b>13.05</b> | <b>Lunch break with poster session</b>                                 |                                  |



# Saturday, March 7, 2020

## Session VII

### New and emerging therapeutic approaches for IBD

**Chair:** J.O. Lindsay, London; E.V. Loftus, Rochester

- |              |  |                             |
|--------------|--|-----------------------------|
| <b>14.05</b> | What is the better patient profile for vedolizumab treatment?                  | W.J. Sandborn,<br>San Diego |
| <b>14.30</b> | Ustekinumab and other interleukin-23 inhibitors for inflammatory bowel disease | B.E. Sands,<br>New York     |
| <b>14.55</b> | JAK inhibitors: A new kid in the block   | S. Ghosh,<br>Birmingham     |
| <b>15.20</b> | Future therapeutic targets in IBD  | S. Schreiber,<br>Kiel       |
| <b>15.45</b> | <b>Coffee break with poster session</b>  |                             |

## Session VIII

### Special situations in IBD

**Chair:** C.N. Bernstein, Winnipeg; S. Singh, San Diego

- |              |   |   |
|--------------|---|---|
| <b>16.15</b> | Sexual dysfunction and pregnancy                                      | C.J. van der Woude,<br>Rotterdam          |
| <b>16.40</b> | Impact of infections in the course and treatment of patients with IBD | G. Rogler,<br>Zurich                      |
| <b>17.05</b> | IBD a systemic disease: Extraintestinal manifestations                | R. Panaccione,<br>Calgary                 |
| <b>17.30</b> | <b>Closing Remarks</b>  | J.K. Yamamoto-<br>Furusho,<br>Mexico City |



## Poster Abstracts

1. Hematological scales as indicators of the exacerbation in ulcerative colitis patients – A single-center experience  
H. Cichoż-Lach, A. Michalak, K. Laskowska, P. Radwan, B. Kasztelan-Szczerbińska (Lublin, PL)
2. Clinical value of lactulose breath test in diagnosis of small intestinal bacterial overgrowth in ulcerative colitis and irritable bowel syndrome  
Y. Cortés Aguilar, G. Priego Figueroa, F. Ruíz Montenegro Cortés, J. Valenzuela Pérez, H. Gómez Rodríguez, C. Jaramillo Buendia, E. Rodríguez Magaña (Guadalajara, MX)
3. Faecal microbiota transplantation: An emerging treatment for ulcerative colitis  
A. Cunningham, M. Hitchings, D. Harris (Swansea, GB)
4. Cerebellar large B-cell lymphoma in a patient on anti-TNF $\alpha$  treatment for Crohn's disease.  
O. Daboussi, J. Boucher, A. Herber (Le Coudray, FR)
5. Prevalence and risk factors of malnutrition in Crohn's disease patients  
O. Daboussi, M. Luwawu, A. Herber (Le Coudray, FR)
6. CONUT score: A promising tool for nutritional assessment and severity evaluation in ulcerative colitis patients  
J. de León Rendón, N. Gracida Mancilla, R. López Pérez, Y. Gutiérrez Grobe, B. Jiménez Bobadilla, J. Villanueva Herrero (Mexico City, MX)
7. Neutrophil/lymphocyte ratio as a severity predictor in ulcerative colitis  
J. de León Rendón, N. Gracida Mancilla, R. López Pérez, Y. Gutiérrez Grobe, B. Jiménez Bobadilla, J. Villanueva Herrero (Mexico City, MX)
8. Gene expression profiling of mediators associated to the inflammatory pathways in the intestinal tissue from patients with ulcerative colitis  
G. Fonseca-Camarillo, E. Iturriaga-Goyon, R. Barreto-Zuñiga, L. Salazar-Salas, A. Peredo-Escárcega, J. Yamamoto-Furusho (Mexico City, MX)
9. Intestinal expression of interleukin-27 by immune cells in patients with inflammatory bowel disease  
G. Fonseca-Camarillo, J. Furuzawa-Carballeda, J. Yamamoto-Furusho (Mexico City, MX)
10. Overexpression of metalloproteinases-10 and -23 (MMP10, MMP23B) in inflammatory bowel disease  
G. Fonseca-Camarillo, J. Furuzawa-Carballeda, J. Yamamoto-Furusho (Mexico City, MX)
11. Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis  
G. Fonseca-Camarillo, E. Iturriaga-Goyón, J. Yamamoto Furusho (Mexico City, MX)

12. Defensins alpha 5 and 6 are up-regulated in the colonic mucosa from patients with ulcerative colitis and are associated with histological activity  
G. Fonseca -Camarillo, J. Yamamoto-Furusho (Mexico City, MX)
13. Characterization of TOB/BTG family proteins in intestinal tissue of patients with inflammatory bowel disease and controls  
G. Fonseca Camarillo, G. Fonseca Camarillo, B. Martínez Benítez, J. Furuzawa Carballeda, R. Barreto Zuñiga, Á. Priego Ranero, J. Yamamoto Furusho (Mexico City, MX)
14. A comprehensive, multiomic diet intervention study comparing a low fat, high fiber diet to an idealized standard American diet in ulcerative colitis patients  
J. Fritsch, A. Quintero, J. Pignac-Kobinger, L. Garces, A. Santander, I. Fernandez, B. Yuguang, D. Kwon, M. Qingqing, C. Chen, O. Damas, N. Solis, D. Kerman, A. Desphande, M. Abreu (Miami, Minneapolis, US)
15. Concerns of patients with inflammatory bowel disease and perception of risks and benefits of medical, surgical and alternative therapies  
F. Gomollón, P. Belanche, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo, A. Lué (Zaragoza, Huesca, ES)
16. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis-related fibrosis in patients with inflammatory bowel disease  
F. Gomollón, P. Alós, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo (Zaragoza, ES)
17. Risk of anxiety, depression and poor quality of life in patients with inflammatory bowel disease  
F. Gomollón, P. Belanche, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo, A. Lué (Zaragoza, Huesca, ES)
18. The relationship between undernutrition and anemia in ulcerative colitis patients: Cross-sectional study results  
S. Ivanov, Y. Uspenskiy, Y. Fominikh, I. Khoroshilov (St. Petersburg, RU)
19. Anemia in patients with intestinal inflammatory disease in a reference center in Medellin-Colombia  
F. Juliao, M. Arrubla, L. Osorio, J. Camargo, J. Londoño, C. Cáceres, J. Carvajal, G. Mosquera, J. Donado (Medellin, CO)
20. Characterization of the intestinal inflammatory disease in Colombia: Results of a national registry  
F. Juliao, F. Puentes, R. López, M. Saffon, G. Reyes, V. Parra, M. Galiano, M. Barraza, J. Molano, E. Alvarez, R. Corrales, L. Vargas, P. Alvarez, L. Limas, P. Yance, H. Ballen, D. Felha, J. Bareño (Medellin, Manizales, Pereira, Monteria, Barranquilla, Bogota, Tunja, Santa Marta, Cartagena, CO)
21. Cross-sectional study using real world data on the active detection of patients with inflammatory bowel disease in Kazakhstan  
J. Kaibullayeva, A. Ualiyeva, A. Oshibayeva, A. Dushpanova, A. Nersesov, A. Nargelova, D. Kushimova, Y. Bazargaliyev, A. Nauryzbayeva, I. Losinskaya, E. Gladysheva, A. Eskozhina, B. Kuzhakhmetov, K. Zhylykybayeva, A. Oleinik,

- A. Duisenova, A. Kurmangaliyeva, S. Aliyeva, N. Kuanysh, T. Tsoy, L. Syzdykova, G. Mutaliyeva, M. Kalisayeva, S. Beisenova, D. Satkeyeva, E. Kuantay, A. Anefiyayeva, N. Ashimova, Z. Sopiyeveva, G. Zaurbayeva, M. Khozhakhmedova, N. Abu, N. Aldabergenova, G. Boskina, A. Tolebai, A. Seitkazyeva, G. Nuraliyeva, A. Zeinetay, D. Borash, A. Gainutdin, G. Ibabayeva, P. Medetova, G. Oshakbayeva, A. Tanbayeva, S. Kuldeyev, A. Tanabayeva, Y. Duisebaev, E. Tagiyev, G. Jakupova, S. Bizhigitova, R. Dossanova (Almaty, Aktobe, Astana, Karaganda, Pavlodar, Petropavlovsk, Kostanay, Semey, Ust-Kamenogorsk, Shymkent, Taraz, Kokshetau, KZ)
22. Administration of biosimilar drugs to IBD patients  
M. Konecny (Olomouc, CZ)
  23. Deviations in platelet and red blood cell indices in ulcerative colitis patients treated with vedolizumab  
A. Michalak, H. Cichoż-Lach, K. Laskowska, P. Radwan, B. Kasztelan-Szczerbińska (Lublin, PL)
  24. Quality of life in patients with inflammatory bowel disease: About a Tunisian monocentric study  
S. Nsibi, R. Ennaifer, M. Ayari, B. Bouchabou, F. Ben Farhat, H. Ben Nejma (La Marsa, TN)
  25. Phenotypic analysis of patients with inflammatory bowel disease: 23-year data of a center in a South American country  
C. Paez Cancelado, B. Mendoza De Molano, R. García Duperly, A. Rey Rubiano, R. López Panqueva, E. Londoño Schimmer, J. Padrón Mercado, M. Mejía Arango, R. Vallejo Madroñero, J. Park (Bogota, CO)
  26. Epidemiological and clinical characterization of inflammatory bowel disease (IBD) in Latin America and the Caribbean: A multicenter study (EPI-LATAM IBD) from the Pan American Crohn's and Colitis Organization (PANCCO)  
N. Parra-Holguín, J. Yamamoto-Furusho, E. Grupo-Colombiano, F. Bosques-Padilla, G. Veitia-Velásquez, E. Torres, F. Piñol-Jiménez, S. Bautista, A. Frías-Santana, K. Villa-Ovalles, G. Otoya-Moreno, B. Iadé Vergara; Study-Group EPI-LATAM (Mexico City, Monterrey, MX; Bogota, CO; Caracas, VE; San Juan, PR; Habana, CU; Santo Domingo, DO; Lima, PE; Montevideo, UY)
  27. Experience on the use of methotrexate in Crohn's disease from a third care level hospital  
N. Parra-Holguín, J. Yamamoto-Furusho (Mexico City, MX)
  28. High frequency of primary hypothyroidism in Mexican patients with inflammatory bowel disease  
N. Parra-Holguín, J. Yamamoto-Furusho (Mexico City, MX)
  29. Impact of fatigue on the quality of life and sleep in Mexican patients with inflammatory bowel disease  
N. Parra-Holguín, J. Yamamoto-Furusho, A. Fresán-Orellana (Mexico City, MX)

30. Effect of vedolizumab on extraintestinal manifestations of inflammatory bowel diseases  
G. Piovezani Ramos, N. McDonald, L. Janssens, B. Al Bawardy, J. Davis, E. Loftus (Rochester, New Haven, US)
31. Ulcerative colitis with sudden exacerbation and the relationship with *Clostridioides difficile* infection: An observational study  
S. Scharrer-Cabello, D. Benavides-Salgado, J. Guerrero-Tamez, C. Alfaro-Rivera, E. Yin-Bañuelos, B. González-Gómez, J. Jáquez-Quintana, F. Bosques-Padilla (Monterrey, Baja California, MX)
32. The relationship between the duration of the diagnosis of IBD and clinical features of the illness  
M. Skalinskaya, E. Skazyvaeva, I. Bakulin, A. Vardanyan, K. Ivanova, I. Rasmagina, D. Komarova (St. Petersburg, Moscow, RU)
33. The frequency of joints manifestations of inflammatory bowel disease in the practice of a rheumatologist  
O. Sulima, V. Sulyma (Dnipro, UA)
34. The results of complex treatment of patients with inflammatory bowel diseases using 5-aminosalicylic acid (5-ASA) drugs, corticosteroids, immunosuppressants and biological therapy  
V. Sulyma, Y. Bereznytskyi, V. Gaponov, S. Malinovskyj, I. Yuschenko, O. Sulima (Dnipro, UA)
35. The presence of pancolitis was associated with the development of any type of neoplasia in patients with ulcerative colitis  
J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)
36. Frequency of pharmacologic intolerance in Mexican patients with ulcerative colitis  
J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)
37. Socioeconomic characteristics are associated with clinical course in Mexican patients with ulcerative colitis  
J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)
38. TRPV4 protein expression is low in Mexican patients with severe ulcerative colitis  
J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)
39. The multidrug resistant proteins (MRPs) in ulcerative colitis (UC)  
M. Villeda-Ramírez, G. Fonseca-Camarillo, J. Yamamoto-Furusho (Mexico City, MX)
40. Global hospitalization trends for Crohn's disease and ulcerative colitis: Systematic review with temporal analyses  
J. Windsor, M. Buie, S. Coward, R. Gearry, T. Hansen, J. King, P. Kotze, C. Ma, S. Ng, N. Panaccione, R. Panaccione, J. Quan, F. Underwood, G. Kaplan (Calgary, CA; Christchurch, NZ; Curitiba, BR; Sha Tin, HK)

41. The penetrance of IBD through a population: Comparison of the relative global incidence and prevalence of ulcerative colitis and Crohn's disease  
J. Windsor, M. Buie, S. Coward, R. Gearry, T. Hansen, J. King, P. Kotze, C. Ma, S. Ng, N. Panaccione, R. Panaccione, J. Quan, F. Underwood, G. Kaplan  
(Calgary, CA; Christchurch, NZ; Curitiba, BR; Sha Tin, HK)
42. Diagnostic utility of the neutrophil-platelet ratio (NeuPla ratio) as a marker of activity in patients with ulcerative colitis  
J. Yamamoto-Furusho, E. Mendieta-Escalante (Mexico City, MX)
43. High correlation between fecal calprotectin and a Novel Integral Index for evaluating disease activity in ulcerative colitis patients  
J. Yamamoto-Furusho, E. Mendieta-Escalante (Mexico City, MX)

## List of Speakers, Moderators and Scientific Organizers

### **Maria T. Abreu, M.D.**

Professor of Medicine  
University of Miami  
Gautier Medical Research Building,  
Room #510  
1011 NW 15th Street  
Miami, FL 33136  
USA  
mabreu1@med.miami.edu

### **Prof. Dr. Willem A. Bemelman**

Department of Surgery  
Tytgat Institute for Liver &  
Intestinal Research  
University van Amsterdam  
Meibergdreef 9  
1105 AZ Amsterdam  
The Netherlands  
w.a.bemelman@amc.uva.nl

### **Dr. Charles N. Bernstein**

Department of Gastroenterology  
University of Manitoba  
804 F-175 McDermot Avenue  
Winnipeg, MB R3E 3P4  
Canada  
charles.bernstein@med.umanitoba.ca

### **Dr. Francisco J. Bosques Padilla**

Servicio de Gastroenterología  
Hospital Universitario  
Dr. José Eleuterio González  
Universidad Autónoma de Nuevo León  
64710 Monterrey, N.L.  
Mexico  
fbosques58@hotmail.com

### **Prof. Dr. Franck Carbonnel**

Service d'Hépatogastroentérologie  
Hôpital de Bicêtre  
78 rue du Général Leclerc  
94275 Le Kremlin Bicêtre  
France  
franck.carbonnel@bct.aphp.fr

### **Adam S. Cheifetz, M.D.**

Professor of Medicine  
Harvard School of Medicine  
Center for Inflammatory Bowel Disease  
Beth Israel Deaconess Medical Center  
330 Brookline Ave  
Rabb 425  
Boston, MA 02215-5400  
USA  
acheifetz@bidmc.harvard.edu

### **Prof. Dr. André D'Hoore**

Department of Abdominal Surgery  
University Hospital Leuven  
Herestraat 49  
3000 Leuven  
Belgium  
andre.dhoore@uzleuven.be

### **Prof. Dr. Axel Dignass**

Medizinische Klinik I  
AGAPLESION  
Markus Krankenhaus  
Wilhelm-Epstein-Str. 4  
60431 Frankfurt  
Germany  
axel.dignass@fdk.info

### **Marla C. Dubinsky, M.D.**

Professor of Pediatrics  
The Susan & Leonard Feinstein  
IBD Clinical Center  
Suite 1165W  
17 East 102nd Street, 5th Floor  
New York, NY 10029  
USA  
marla.dubinsky@mssm.edu

### **Dr. Marjolijn Duijvestein**

Department of Gastroenterology and  
Hepatology (Room PK 2 x 140)  
Amsterdam UMC  
De Boelelaan 1117  
1081 HV Amsterdam  
The Netherlands  
m.duijvestein@amsterdamumc.nl

**Claudio Fiocchi, M.D.**

Professor of Medicine  
Department of Inflammation & Immunity  
Cleveland Clinic  
9500 Euclid Avenue  
Cleveland, OH 44195  
USA  
fiocchc@ccf.org

**Prof. Dr. Subrata Ghosh**

Institute of Translational Medicine  
University of Birmingham  
Birmingham B15 2TT  
Great Britain  
ghoshs@bham.ac.uk

**Prof. Dr. Fernando Gomollón**

IBD Unit  
Hospital Clinico Universitario "Losano Blesa"  
Facultad de Medicina  
Fundación del Instituto de Investigación  
Sanitaria de Aragón (IIS Aragón)  
Avenida San Juan Bosco 15  
50009 Zaragoza  
Spain  
fgomollon@gmail.com

**Prof. Dr. Gilaad Kaplan**

Division of Gastroenterology and  
Hepatology  
Inflammatory Bowel Disease Clinic  
Cumming School of Medicine  
University of Calgary  
Teaching Research and Wellness Building  
Room 3D03-18, 3280 Hospital Drive NW  
Calgary, AB T2N 4Z6  
Canada  
gkaplan@ucalgary.ca

**Prof. Dr. James O. Lindsay**

Consultant Gastroenterologist  
The Royal London Hospital  
Bart's Health NHS Trust  
Whitechapel  
London E1 1BB  
Great Britain  
james.lindsay@bartshealth.nhs.uk

**Edward V. Loftus, M.D.**

Professor of Medicine  
Division of Gastroenterology  
and Hepatology  
Mayo Clinic  
200 First Street SW  
Rochester, MN 55905  
USA  
loftus.edward@mayo.edu

**Javier Martín de Carpi, M.D., Ph.D.**

Department of Gastroenterology,  
Hepatology and Nutrition  
Hospital Sant Joan de Déu Barcelona  
Passeig de Sant Joan de Déu, 2  
08950 Esplugues de Llobregat, Barcelona  
Spain  
javiermartin@sjdhospitalbarcelona.org

**Prof. Dr. Pia Munkholm**

Department of Gastroenterology  
North Zealand University Hospital  
Frederikssundsvej 30  
3600 Frederikssund  
Denmark  
pia.munkholm@regionh.dk

**Prof. Dr. Remo Panaccione**

Inflammatory Bowel Disease Clinic  
Cumming School of Medicine  
University of Calgary  
Teaching Research and Wellness Building  
Room 6D30, 3280 Hospital Drive NW  
Calgary, AB, T2N 4Z6  
Canada  
rpanacci@ucalgary.ca

**Prof. Dr. Zhihua Ran**

Department of Gastroenterology  
Renji Hospital  
Shanghai Jiaotong University  
160 Pu Jian Rd., Pudong Distr.  
200001 Shanghai  
China  
zhihuan@vip.163.com

**Feza Remzi, M.D.**

Professor of Surgery  
Inflammatory Bowel Disease Center  
240 East 38th Street, 23rd Floor  
New York, NY 10016  
USA  
feza.remzi@nyulangone.org

**Dr. Jordi Rimola**

Department of Radiology  
Hospital Clinic de Barcelona  
C/Villarroel 170  
08036 Barcelona  
Spain  
jordirimola@gmail.com

**Prof. Dr. Dr. Gerhard Rogler**

Klinik für Gastroenterologie &  
Hepatology  
Universitätsspital Zürich  
Rämistr. 100  
8091 Zürich  
Switzerland  
gerhard.rogler@usz.ch

**William J. Sandborn, M.D.**

Professor of Medicine  
Division of Gastroenterology  
University of California San Diego  
9500 Gilman Drive, MC 0956  
La Jolla, CA 92093  
USA  
wsandborn@ucsd.edu

**Bruce E. Sands, M.D.**

Professor of Medicine  
Icahn School of Medicine at Mount Sinai  
One Gustave L. Levy Place, Box 1069  
New York, NY 10029  
USA  
bruce.sands@mssm.edu

**Prof. Dr. Stefan Schreiber**

Klinik für Innere Medizin I  
Universitätsklinikum  
Schleswig-Holstein, Campus Kiel  
Arnold-Heller-Str. 3 (Haus 6)  
24105 Kiel  
Germany  
s.schreiber@mucosa.de

**Bo Shen, M.D.**

Professor of Medicine  
Columbia University Medical Center  
New York Presbyterian Hospital  
Herbert Irving Pavilion  
161, Fort Washington Avenue  
New York, NY 10032  
USA  
bs3270@cumc.columbia.edu

**Siddarth Singh, M.D., M.Sc.**

Assistant Professor of Medicine  
Div. of Gastroenterology and  
Div. of Biomedical Informatics  
University of California San Diego  
9452 Medical Center Dr., ACTRI 1W501  
La Jolla, CA 92093  
USA  
sis040@ucsd.edu

**A. Hillary Steinhart, M.D.**

Professor of Medicine  
Mount Sinai Hospital IBD Centre  
University of Toronto  
445-600 University Avenue  
Toronto, ON M5G 1X5  
Canada  
hillary.steinhart@sinaihhealthsystem.ca

**Prof. Dr. C. Janneke van der Woude**

Afd. Gastroenterologie  
Erasmus Medical Center  
's-Gravendijkwal 230  
3015 CE Rotterdam  
The Netherlands  
c.vanderwoude@erasmusmc.nl

**Prof. Dr. Michael Vieth**

Institut für Pathologie  
Klinikum Bayreuth  
Preuschwitzer Str. 101  
95445 Bayreuth  
Germany  
vieth.lkpathol@uni-bayreuth.de

**Prof. Dr. Jesús K. Yamamoto-Furusho**

Clinica de Enfermedad Inflammatoria  
Intestinal  
Departamento de Gastroenterología  
Instituto Nacional de Ciencias  
Médicas y Nutrición Salvador Zubirán  
Segundo piso, Calle Vasco de Quiroga 15  
Colonia Belisario Domínguez Sección XVI  
Delegación Tlalpan. C.P.  
14080 Ciudad de México  
Mexico  
kazuofurusho@hotmail.com



## Congress Office

**During** Symposium 218

**Congress Office Telephone:** +49-175-7795-327

### Opening Hours:

Thursday, March 5, 2020 16.00 – 21.00 h

Friday, March 6, 2020 8.00 – 18.30 h

Saturday, March 7, 2020 8.30 – 17.45 h

### Congress Venue:

Hyatt Regency Hotel  
Campos Elíseos 204  
Polanco Chapultepec  
11560 Mexico City  
Mexico

## Congress Fees

Scientific Program of Symposium 218 EUR 200

Students (copy of student ID required) EUR 100

**\*\*\*OR\*\*\***

Day Ticket EUR 120

Students (copy of student ID required) EUR 60

### The congress fees include:

- Pre-Opening and Welcome on Thursday, March 5, 2020
- Refreshments during coffee breaks
- Lunch on Friday, March 6 and on Saturday, March 7, 2020
- Networking with light refreshments on Friday, March 6, 2020
- A copy of the abstract volume
- A copy of the final program

## Admission to Scientific Program

For admission to scientific events your name badge should be clearly visible. Accompanying persons are not permitted during the conference at any time.

## Airport

Hyatt Regency Hotel is located in the upscale Polanco neighborhood, near Paseo de la Reforma and Chapultepec Park.

The distance between the airport and the hotel is around 17 kilometers and a car ride will take approximately 40 minutes.

Travelling by taxi is the best way to get to and from Mexico City Airport. It is strongly recommended to pick up an authorized taxi and avoid rides offered by non-authorized drivers.

Taxi ranks are located at the entrance of both terminals: Terminal 1 and Terminal 2 (international and domestic).

Only taxis by SCT Secretaría de Comunicaciones y Transportes are authorized to provide service at the airport. Currently the following taxi companies offering service at Mexico Airport (MEX): Porto Taxi, Sitio 300, Nueva Imagen, Excelencia, Confort and Yellow Cab.

You can purchase your ticket at the booths near the arrival gates in the walkway area. You can also use Uber, which is safe as well.

Further information can be found under: <https://www.mexico-airport.com/taxi.php>  
Or ask the concierge of the hotel to organize your transfer.

## Conflicts of Interest

Members of the scientific committee declare the following potential conflicts of interest: M.T. Abreu: Prometheus, Takeda, Eli Lilly, Pfizer, AbbVie, Janssen, Focus Medical Communications, Celgene, Shire; F.J. Bosques Padilla: AbbVie, Janssen, Takeda; F. Gomollón: MSD, AbbVie, Janssen, Tillots, Takeda; J.K. Yamamoto-Furusho: AbbVie, Alfasigma, Almiral, Bristol Myers Squibb, Celltrion, Danone, Farmasa, Ferring, Grunenthal, Janssen, Pfizer, Takeda.

# International Symposia and Workshops

*Scientific Dialogue  
in the Interest of  
Therapeutic Progress*



Workshop  
**Primary Liver Cancer –  
Emerging Concepts and Novel  
Treatments**

Mainz, Germany  
February 13–14, 2020



Symposium 218  
**Current Challenges of  
Inflammatory Bowel Disease**

Mexico City, Mexico  
March 6–7, 2020



Workshop  
**Microscopic Colitis –  
New Insights and Recommendations**

Copenhagen, Denmark  
May 21, 2020



Symposium 219  
**IBD-Patients – In the Center of Care**

Copenhagen, Denmark  
May 22–23, 2020



Symposium 220  
**XXVI International Bile Acid Meeting:  
Bile Acids in Health and Disease 2020**

Amsterdam, The Netherlands  
July 10–11, 2020



Symposium 221  
**IBD Management in the New Decade:  
Old Myths and New Realities**

Athens, Greece  
October 2–3, 2020



Symposium 222  
**Eosinophilic Esophagitis –  
Advanced Science for Everyday  
Challenges in Clinical Practice**

Zurich, Switzerland  
November 20–21, 2020


FALK FOUNDATION e.V.



Leinenweberstr. 5  
79108 Freiburg  
Germany

Congress Department  
Tel.: +49-761-1514-125  
Fax: +49-761-1514-359  
E-Mail: [symposia@falk-foundation-symposia.org](mailto:symposia@falk-foundation-symposia.org)  
[www.falk-foundation-symposia.org](http://www.falk-foundation-symposia.org)

# 2020



## Organized by:

FALK FOUNDATION e.V.



Leinenweberstr. 5  
79108 Freiburg  
Germany

Congress Department  
Telephone: +49-761-1514-125  
Telefax: +49-761-1514-359  
E-Mail: [symposia@falk-foundation-symposia.org](mailto:symposia@falk-foundation-symposia.org)  
[www.falk-foundation-symposia.org](http://www.falk-foundation-symposia.org)